To potentiate the clinical and industrial applications of cell therapy

October 31, 2017

Almost all the treatments that are currently being carried out at the clinic are based on somatic stem cells while there is still a huge potential to unlock for the use of pluripotent cells which can differentiate into almost all types of tissues. Allogenic treatments can be generated from pluripotent stem cells obtained from embryos not used for reproductive purposes while autologous treatments come from patient’s cells reprogrammed into iPSCs. Both types of treatment have advantages and disadvantages. While allogeneic treatment has the advantage of immediacy, it has the disadvantage of possible rejections, autologous avoid rejection but make it impossible for off-the-shelf product. From the experimental development point of view, it is necessary to promote the expansion of cells in GMP environments and protocolize new methods of expansion/differentiation of specific cells for specific diseases but also generic to obtain ready-to-use products.


ADVANCE(CAT) intends to promote the use of somatic stem cells towards clinical application and industrial exploitation. Further, ADVANCE(CAT) works on the potential of pluripotent stem cells, both PSCs and ESCs, for specific diseases.

To potentiate the clinical applications of tissue engineering

October 31, 2017

Regenerative medicine in its most strict terms aims to regenerate tissues or organs for therapeutic purposes. For this purpose, it is necessary to reproduce as much as possible the niche of the different tissues that are intended to be replaced. Extracellular matrix contributes structurally to the niche but is also a source of factors that contribute to maintaining and differentiating cells correctly.


Current decellularization techniques for tissue offer ways to obtain natural extracellular matrix but new artificial production methods allow to create extracellular matrix or scaffolds in the lab. Artificial scaffolds can be generated by 3D printing of biomaterials. These bioprinters work in certain environmental conditions that must be made compatible with the GMP environments if they are to be used for the clinic of certain diseases.


ADVANCE(CAT) intends to develop new artificial tissue production systems by combining both natural and artificial scaffolds with cells. ADVANCE(CAT) will develop 3D printing techniques of scaffolds in GMP environments.

Please reload